

**Te Whatu Ora** Health New Zealand Capital, Coast and Hutt Valley



# A workflow for longitudinal biomarker discovery studies in human disease: a focus on major surgery



Kathryn Hally, PhD

Lecturer, University of Otago ISAC Marylou Ingram Scholar (2024-2028) Surgical Immunology Research Group

kathryn.hally@otago.ac.nz

### Ko wai au?











**Ko Remutaka te maunga e rū nei taku ngākau.** The Remutaka Range is my mountain.

**Ko Te Awa Kairangi te awa e mahea nei aku māharahara.** The Hutt River is my river.

Nō Te Awa Kairangi ki Tai ahau. Kei Te Awa Kairangi ki Tai ahau e noho ana. I live in Lower Hutt.

#### He Pūkenga ahau mō Ōtākou Whakaihu Waka ki Poneke.

I work at the University of Otago, Wellington campus.

### Acknowledgements



#### **Surgical Immunology Research Group**

- <u>Connor Davis</u>
- Emma Thompson
- Thomas Hartono
- Eushin Kang



#### Connor Davis, Assistant Research Fellow

#### Wellington Cardiovascular Research Group

- <u>Ceridwyn Jones</u>
- Dr Ana Holley
- AProf Peter Larsen
- Michael Roberts





#### AGHAN Malaghan Institute of Medical Research

<u>Kate Pilkington</u>

### Te Whatu Ora

Health New Zealand Capital, Coast and Hutt Valley

- Te Whatu Ora Capital, Coast and Hutt Valley
- Dr Lupe Taumoepeau
- Dr Scott Harding



**Project funding** 



#### HRC Emerging Researcher First Grant



**Deans Research Grant** 

#### **Conference funding**









Group aim: to harness the immune response to surgery for biomarker discovery

To design panels for monitoring the phenotype of circulating human immune cells.

To monitor the immune response to major surgery. To determine what cell phenotypes are associated with a complicated postoperative course.



### Predicting adverse postoperative recovery



Panel design





#### Comparing platelet aggregation across isolations R G S **Considerations for: cell isolation** \*EDTA-anticoagulated peripheral blood **Density isolation Magnetic isolation** "False" expression of markers co-expressed on platelets 10 **46%** <u>11%</u> 0.4% 0.1% **Density isolation Magnetic isolation** of CD45<sup>+</sup> of CD45<sup>+</sup> of CD45<sup>+</sup> cells are CD235a<sup>+</sup> of CD45<sup>+</sup> cells are CD235a<sup>+</sup> cells are (±CD42b<sup>+</sup>) cells are (±CD42b<sup>+</sup>) 23% 3%



Panel 3: T, B and NK cells 🤇





#### Considerations for: cell isolation → regents



#Is Fc blocking during magnetic isolation sufficient for staining?\*BioLegend TruStain FcX blocker and True-Stain Monocyte Blocker





Considerations for: cell isolation → regents





#Is Fc blocking during magnetic isolation sufficient for staining?\*BioLegend TruStain FcX blocker and True-Stain Monocyte Blocker



Monocyte blocker





#### Considerations for: cell isolation → regents





#Is Fc blocking during magnetic isolation sufficient for staining?\*BioLegend TruStain FcX blocker and True-Stain Monocyte Blocker





### IRG S

#### Considerations for: cell isolation → regents





CD15-

**BV711** 







### Improving marker resolution with sequential staining



Considerations for: cell isolation  $\rightarrow$  regents  $\rightarrow$  sequential staining











Considerations for: cell isolation  $\rightarrow$  regents  $\rightarrow$  sequential staining





**Full stain** 





### Validating batch preparation of the antibody cocktails

7

Considerations for: cell isolation  $\rightarrow$  regents  $\rightarrow$  sequential staining  $\rightarrow$  longitudinal monitoring



#### Acceptable after storage



#### Added 'fresh' for each sample





Connor Davis, Assistant Research Fellow



### To conclude

SIR G

